Challenges and Prospects in Geriatric Epilepsy Treatment: the Role of the Blood-brain Barrier in Pharmacotherapy and Drug Delivery

Overview

Journal Front Aging Neurosci

Specialty Geriatrics

Date 2024 Feb 23

PMID 38389560

Authors

Xin Chen

Juan Luo

Min Song

Liang Pan

Zhichuang Qu

Bo Huang

Sixun Yu

Haifeng Shu

Affiliations

Soon will be listed here.

Abstract

The blood-brain barrier (BBB) is pivotal in maintaining neuronal physiology within the brain. This review delves into the alterations of the BBB specifically in the context of geriatric epilepsy. We examine how age-related changes in the BBB contribute to the pathogenesis of epilepsy in the elderly and present significant challenges in pharmacotherapy. Subsequently, we evaluate recent advancements in drug delivery methods targeting the BBB, as well as alternative approaches that could bypass the BBB's restrictive nature. We particularly highlight the use of neurotropic viruses and various synthetic nanoparticles that have been investigated for delivering a range of antiepileptic drugs. Additionally, the advantage and limitation of these diverse delivery methods are discussed. Finally, we analyze the potential efficacy of different drug delivery approaches in the treatment of geriatric epilepsy, aiming to provide insights into more effective management of this condition in the elderly population.

Citing Articles

Advancing Central Nervous System Drug Delivery with Microtubule-Dependent Transcytosis of Novel Aqueous Compounds.

Zhang M, Zhong S, An L, Xiang P, Hu N, Huang W Biomater Res. 2024; 28:0051.

PMID: 39050687 PMC: 11268840. DOI: 10.34133/bmr.0051.

References

Hernandez-Ronquillo L, Adams S, Ballendine S, Tellez-Zenteno J . Epilepsy in an elderly population: Classification, etiology and drug resistance. Epilepsy Res. 2018; 140:90-94. DOI: 10.1016/j.eplepsyres.2017.12.016. View

Rapti K, Louis-Jeune V, Kohlbrenner E, Ishikawa K, Ladage D, Zolotukhin S . Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther. 2011; 20(1):73-83. PMC: 3255603. DOI: 10.1038/mt.2011.177. View

Milikovsky D, Ofer J, Senatorov Jr V, Friedman A, Prager O, Sheintuch L . Paroxysmal slow cortical activity in Alzheimer's disease and epilepsy is associated with blood-brain barrier dysfunction. Sci Transl Med. 2019; 11(521). DOI: 10.1126/scitranslmed.aaw8954. View

Segarra M, Aburto M, Acker-Palmer A . Blood-Brain Barrier Dynamics to Maintain Brain Homeostasis. Trends Neurosci. 2021; 44(5):393-405. DOI: 10.1016/j.tins.2020.12.002. View

Salinas S, Schiavo G, Kremer E . A hitchhiker's guide to the nervous system: the complex journey of viruses and toxins. Nat Rev Microbiol. 2010; 8(9):645-55. DOI: 10.1038/nrmicro2395. View

Noe F, Pool A, Nissinen J, Gobbi M, Bland R, Rizzi M . Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy. Brain. 2008; 131(Pt 6):1506-15. DOI: 10.1093/brain/awn079. View

Sen A, Jette N, Husain M, Sander J . Epilepsy in older people. Lancet. 2020; 395(10225):735-748. DOI: 10.1016/S0140-6736(19)33064-8. View

Olmez I, Ozyurt H . Reactive oxygen species and ischemic cerebrovascular disease. Neurochem Int. 2011; 60(2):208-12. DOI: 10.1016/j.neuint.2011.11.009. View

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

10.

Fang Z, Chen S, Qin J, Chen B, Ni G, Chen Z . Pluronic P85-coated poly(butylcyanoacrylate) nanoparticles overcome phenytoin resistance in P-glycoprotein overexpressing rats with lithium-pilocarpine-induced chronic temporal lobe epilepsy. Biomaterials. 2016; 97:110-21. DOI: 10.1016/j.biomaterials.2016.04.021. View

11.

Gerstner E, Fine R . Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol. 2007; 25(16):2306-12. DOI: 10.1200/JCO.2006.10.0677. View

12.

Parkinson F, Friesen J, Krizanac-Bengez L, Janigro D . Use of a three-dimensional in vitro model of the rat blood-brain barrier to assay nucleoside efflux from brain. Brain Res. 2003; 980(2):233-41. DOI: 10.1016/s0006-8993(03)02980-9. View

13.

Raleigh D, Marchiando A, Zhang Y, Shen L, Sasaki H, Wang Y . Tight junction-associated MARVEL proteins marveld3, tricellulin, and occludin have distinct but overlapping functions. Mol Biol Cell. 2010; 21(7):1200-13. PMC: 2847524. DOI: 10.1091/mbc.e09-08-0734. View

14.

Pardeshi C, Belgamwar V . Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting. Expert Opin Drug Deliv. 2013; 10(7):957-72. DOI: 10.1517/17425247.2013.790887. View

15.

Foust K, Nurre E, Montgomery C, Hernandez A, Chan C, Kaspar B . Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 2008; 27(1):59-65. PMC: 2895694. DOI: 10.1038/nbt.1515. View

16.

Kodaira H, Kusuhara H, Fujita T, Ushiki J, Fuse E, Sugiyama Y . Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid.... J Pharmacol Exp Ther. 2011; 339(3):935-44. DOI: 10.1124/jpet.111.180398. View

17.

Bernardo-Castro S, Sousa J, Bras A, Cecilia C, Rodrigues B, Almendra L . Pathophysiology of Blood-Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery. Front Neurol. 2020; 11:594672. PMC: 7756029. DOI: 10.3389/fneur.2020.594672. View

18.

Cramer S, Simonsen H, Frederiksen J, Rostrup E, Larsson H . Abnormal blood-brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin. 2013; 4:182-9. PMC: 3872721. DOI: 10.1016/j.nicl.2013.12.001. View

19.

Ji N, Weng D, Liu C, Gu Z, Chen S, Guo Y . Adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of recurrent high-grade glioma. Oncotarget. 2015; 7(4):4369-78. PMC: 4826211. DOI: 10.18632/oncotarget.6737. View

20.

Pardridge W . Blood-brain barrier delivery. Drug Discov Today. 2007; 12(1-2):54-61. DOI: 10.1016/j.drudis.2006.10.013. View